1. |
赵雯. 药品福利管理在我国医疗保险和商业健康保险中的运用. 成都: 西南财经大学, 2014.
|
2. |
高红玉, 周利生. 美国药品福利管理模式的科学价值及其在我国的应用. 价格理论与实践, 2014, (5): 100-102.
|
3. |
Mullins CD, Wang J. Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making. Pharmacoeconomics, 2002, 20(1): 9-21.
|
4. |
曾宪涛, 刘慧, 陈曦, 等. Meta 分析系列之四: 观察性研究的质量评价工具. 中国循证心血管医学杂志, 2012, 4(4): 297-299.
|
5. |
McPherson T, Fontane P, Iyengar R, et al. Utilization and costs of compounded medications for commercially insured patients, 2012-2013. J Manag Care Spec Pharm, 2016, 22(2): 172-181.
|
6. |
Donohue JM, Papademetriou E, Henderson RR, et al. Early marketplace enrollees were older and used more medication than later enrollees; marketplaces pooled risk. Health Aff (Millwood), 2015, 34(6): 1049-1056.
|
7. |
Carroll NV. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies. J Manag Care Spec Pharm, 2014, 20(9): 959-967.
|
8. |
Wu N, Lee YC, Shah N, et al. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. Clin Ther, 2014, 36(8): 1231-1241.
|
9. |
Fiscella RG, Lewis CC, Jensen MK. Topical ophthalmic fourth-generation fluoroquinolones: Appropriate use and cost considerations. Am J Health Syst Pharm, 2007, 64(19): 2069-2073.
|
10. |
Sullivan PW, Nair KV, Patel BV. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. Am J Manag Care, 2005, 11(6): 374-382.
|
11. |
Khandelwal N, Duncan I, Rubinstein E, et al. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions. J Manag Care Pharm, 2012, 18(3): 247-255.
|
12. |
Brennan TA, Dollear TJ, Hu M, et al. An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients. Health Aff (Millwood), 2012, 31(1): 120-129.
|
13. |
French DD, Spehar AM, Campbell RR, et al. Advances in patient safety outpatient benzodiazepine prescribing, adverse events, and costs. Advances in patient safety: From research to implementation (volume 1: Research findings). Washington DC., Agency for Healthcare Research and Quality (US), 2005.
|
14. |
Calabrese D. Comparing pharmacy benefit managers: moving well beyond the simple spreadsheet analysis. Am Health Drug Benefits, 2008, 1(5): 9-19.
|
15. |
Harris KM, Thomas C. Naltrexone and pharmacy benefit management. J Addict Dis, 2004, 23(4): 11-29.
|
16. |
Motheral BR, Heinle SM. Predictors of satisfaction of health plan members with prescription drug benefits. Am J Health Syst Pharm, 2004, 61(10): 1007-1014.
|
17. |
胡海宁, 雷海潮. 美国药品利益管理公司的服务内容. 卫生经济研究, 2002, (3): 18-20.
|
18. |
Meador M. Squeezing the middleman: ending underhanded dealing in the pharmacy benefit management industry through regulation. Ann Health Law, 2011, 20(1): 77-112.
|
19. |
Rentmeester CA, Garis RI. Rebates and spreads: pharmacy benefit management practices and corporate citizenship. J Health Polit Policy Law, 2008, 33(5): 943-963.
|
20. |
Bae JP, Justice PG. Pharmacy benefit management contracting: an assessment from a recent public sector procurement experience. J Health Care Finance, 2002, 29(1): 49-56.
|
21. |
Stevenson JG, Bruhnsen K. Strategies to Improve PBM Management of an Employee Prescription Drug Plan. Am J Pharm Ben, 2015, 7(1): E10-E4.
|
22. |
Olson J, Wickizer M. Outcome evaluation of a pharmacy benefit management-based asthma management program. Clin Sch Rev, 2015, 8(1): 102-129.
|
23. |
Shrank WH, Porter ME, Jain SH, et al. A blueprint for pharmacy benefit managers to increase value. Am J Manag Care, 2009, 15(2): 87-93.
|
24. |
Tsiachristas A, Cramm JM, Nieboer AP, et al. Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants. Cost Eff Resour Alloc, 2014, 12: 17.
|